Cefepime is a fourth-generation cephalosporin antibiotic, effective against a broad spectrum of bacteria, including many Gram-negative pathogens such as Pseudomonas aeruginosa, and some Gram-positive bacteria. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis and death. This compound is particularly valuable for treating complicated infections like pneumonia, urinary tract infections, skin and soft tissue infections, intra-abdominal infections, and bacteremia, especially in hospitalized patients or those with multidrug-resistant strains. Due to its enhanced stability against beta-lactamases and favorable pharmacokinetics, it is primarily administered via intravenous or intramuscular injection.